Piramal Pharma Ltd

- The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027. - The Riverview expansion is largely complete and already serving clients. - Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion. - No new significant capex plans were indicated beyond these projects, suggesting a period of consolidation. - Customer-funded capex related to a specific suite is complete; no further spend planned there. - Future capex excludes amounts spent on the Kenalog acquisition or potential similar deals. - The company is prioritizing capital allocation to areas with anticipated returns, reflected in a recent impairment of certain intangible assets.

- FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. - CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites. - CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings. - On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches. - ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driver in FY27-FY28 and beyond with new customers added. - Consumer Health Care business grew 17% in FY26 and expects continued broad-based growth with premiumization and strategic launches. - API generics business expected to grow modestly, supported by new products and expanded market presence. - Overall, emphasis on sustainable, profitable growth with operating leverage expected to drive faster EBITDA growth than revenue.

- For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses. - EBITDA and PAT are projected to grow faster than revenue in FY27. - The CDMO business will continue to be back-weighted to H2, particularly Q4, due to client delivery timings. - Operating margins are expected to improve as scale increases, with tax rates normalizing around 24-25%. - Long-term net debt-to-EBITDA target is approximately 1, though it remains elevated in the short term due to ongoing capital investments. - Growth drivers include expansion of overseas sites, differentiated specialty products, and momentum in consumer healthcare power brands and e-commerce. - Exceptional charges like intangible asset impairment in FY26 are not expected to recur regularly, with stricter capex prioritization in place. - Overall, management expresses confidence in returning to consistent and profitable growth in FY27 and beyond.

- Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage. - The company has improved RFP-to-order conversion rates, especially with new customers. - A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth. - They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities. - CDMO business revenues were INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year, with modest growth adjusted for temporary de-stocking. - Growth was slower in H1 due to subdued biopharma funding but rebounded strongly in H2, accelerating order inflows.

- There is no explicit mention of any new fundraising through debt or equity planned for FY27. - The company noted ongoing investments and capacity expansions are largely targeted and planned (e.g., Lexington expansion). - Debt level currently operates around a net debt-to-EBITDA ratio of 3.6x, expected to remain range-bound in FY27. - The company aims to reduce net debt-to-EBITDA to around 1x over the long term but expects elevated levels in the near term due to capex. - No mention of equity fundraising; capex for FY27 is estimated at INR 120-135 million, excluding acquisitions like Kenalog. - The company is managing working capital carefully to support cash flow and debt servicing. - Exceptional intangible asset impairment suggests prioritizing capital allocation but no direct references to raising funds.